Adjuvant Capital

Adjuvant Capital is a life sciences venture capital firm that finances promising technologies targeting high-burden public health challenges in historically overlooked markets. The firm makes $10–$25 million preferred equity investments in companies developing drugs, vaccines, diagnostics, and medical devices for neglected infectious diseases, maternal and child health, and antimicrobial resistance. Founded in 2018 by GHIF alumni, Adjuvant raised a $300 million oversubscribed second fund in 2021 with backing from Merck, Novartis, and leading philanthropies, pursuing a 'double-bottom-line' return strategy that combines social impact with financial performance.